MA43755A - Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte - Google Patents

Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Info

Publication number
MA43755A
MA43755A MA043755A MA43755A MA43755A MA 43755 A MA43755 A MA 43755A MA 043755 A MA043755 A MA 043755A MA 43755 A MA43755 A MA 43755A MA 43755 A MA43755 A MA 43755A
Authority
MA
Morocco
Prior art keywords
host
graft
prevention
treatment
methods
Prior art date
Application number
MA043755A
Other languages
English (en)
Inventor
John E Ford
Jessica A Sachs
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA43755A publication Critical patent/MA43755A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA043755A 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte MA43755A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662307896P 2016-03-14 2016-03-14
US201662420825P 2016-11-11 2016-11-11

Publications (1)

Publication Number Publication Date
MA43755A true MA43755A (fr) 2018-11-28

Family

ID=58455657

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043755A MA43755A (fr) 2016-03-14 2017-03-13 Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte

Country Status (12)

Country Link
US (1) US20190077868A1 (fr)
EP (1) EP3430053A1 (fr)
JP (2) JP2019512493A (fr)
KR (2) KR102667332B1 (fr)
CN (2) CN109153721A (fr)
AU (2) AU2017234010B2 (fr)
BR (1) BR112018068625A2 (fr)
CA (1) CA3017758A1 (fr)
IL (1) IL261767A (fr)
MA (1) MA43755A (fr)
MX (1) MX2018011025A (fr)
WO (1) WO2017160700A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116327920A (zh) * 2016-03-14 2023-06-27 千禧制药公司 预防移植物抗宿主疾病的方法
EP3468597A1 (fr) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Méthode de traitement de maladie intestinale inflammatoire
JP2020517671A (ja) * 2017-04-28 2020-06-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小児の障害を処置する方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0808367B1 (fr) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Adressines vasculaires de muqueuses et leurs utilisations
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US20010046496A1 (en) 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
MXPA04011465A (es) 2002-05-24 2005-02-14 Millennium Pharm Inc Inhibidores de ccr9 y metodos de uso de los mismos.
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
MX370489B (es) 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
ES2377979T3 (es) 2004-09-03 2012-04-03 Genentech, Inc. Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
EP1940827B1 (fr) * 2005-09-29 2011-03-16 Elan Pharmaceuticals Inc. Composes de pyrimidinyl amide qui inhibent l'adherence leucocytaire a mediation par vla-4
US20070122404A1 (en) 2005-11-17 2007-05-31 O'keefe Theresa L Humanized immunoglobulin reactive with alpha4beta7 integrin
SG10201801337WA (en) 2009-03-20 2018-03-28 Amgen Inc Alpha-4-Beta-7 Heterodimer Specific Antagonist Antibody
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2012151247A2 (fr) 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION POUR UN ANTICORPS ANTI-α4β7
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
JP2022137024A (ja) 2022-09-21
IL261767A (en) 2018-10-31
EP3430053A1 (fr) 2019-01-23
KR20240074903A (ko) 2024-05-28
BR112018068625A2 (pt) 2019-07-30
WO2017160700A1 (fr) 2017-09-21
KR20180117195A (ko) 2018-10-26
AU2017234010B2 (en) 2024-06-13
CN117298268A (zh) 2023-12-29
CN109153721A (zh) 2019-01-04
AU2024203289A1 (en) 2024-08-01
JP2019512493A (ja) 2019-05-16
US20190077868A1 (en) 2019-03-14
AU2017234010A1 (en) 2018-09-27
MX2018011025A (es) 2019-01-10
CA3017758A1 (fr) 2017-09-21
KR102667332B1 (ko) 2024-05-20

Similar Documents

Publication Publication Date Title
MA46954A (fr) Méthodes de traitement d'états inflammatoires
MA43374A (fr) Méthodes de traitement de tumeurs malignes
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
MA52371A (fr) Méthodes de traitement d'infections dues aux coronaviridae
MA41028A (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
IL265528A (en) aav therapy for Huntington's disease
IL247085A0 (en) Methods for treating Alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
IL266871A (en) Modified oligonucleotides for the treatment of polycystic kidney disease
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
MA43570A (fr) Thérapie génique pour traiter l'hypercholestérolémie familiale
MA47395A (fr) Méthode pour le traitement d'une maladie neurologique
MA41120A (fr) Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3347486A4 (fr) Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
MA43755A (fr) Méthodes de traitement ou de prévention d'une maladie du greffon contre l'hôte
EP3310377A4 (fr) Méthode de traitement de la maladie de crohn
FR3044227B1 (fr) Derives aminophosphiniques pour la prevention et le traitement des douleurs oculaires
MA46967A (fr) Méthodes de traitement de l'arthropathie hémophilique à l'aide de facteurs de coagulation chimériques
EP3142708A4 (fr) Test de diagnostic et de traitement/prévention de la maladie d'alzheimer
EP3137097C0 (fr) Traitement et prévention de la maladie d'alzheimer
EP3439701A4 (fr) Procédé de traitement de la maladie de dupuytren à un stade précoce
MA50582A (fr) Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés